BridgeBio’s acoramidis wins Japan’s approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca’s Alexion to market it.
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Where Today's News Shapes Tomorrow
